<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We compared the sensitivity and specificity of a tissue factor-based assay (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FVR</z:e>) with the addition of a <z:chebi fb="0" ids="16247">phospholipid</z:chebi>/<z:chebi fb="48" ids="30563">silica</z:chebi> preparation, to the commercially available aPTT-based method, APCR (CoatestTM), and a modified aPTT-based method (APCM) which utilized factor V-depleted plasma, for the detection of the <z:e sem="disease" ids="C0584960" disease_type="Disease or Syndrome" abbrv="">factor V Leiden mutation</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>A total of 110 patients were included in this study </plain></SENT>
<SENT sid="2" pm="."><plain>This included 32 patients on <z:chebi fb="0" ids="10034">coumadin</z:chebi> therapy, 7 patients on <z:chebi fb="5" ids="28304">heparin</z:chebi> therapy, 5 patients on both <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> therapy, and 24 patients who were positive for anticardiolipin antibody (ACL) and/or <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> inhibitor (LI) </plain></SENT>
<SENT sid="3" pm="."><plain>Our data demonstrate that the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FVR</z:e> is not affected by anticoagulation treatment or ACL/LI antibodies, whereas in the APCR method, 33 patients cannot be determined either due to the <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy or presence of the ACL and/or LI </plain></SENT>
<SENT sid="4" pm="."><plain>With the APCM method, the clotting endpoint could not be determined in 1 patient due to the presence of a strong LI </plain></SENT>
<SENT sid="5" pm="."><plain>The additional <z:chebi fb="0" ids="16247">phospholipid</z:chebi>/<z:chebi fb="48" ids="30563">silica</z:chebi> material utilized in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FVR</z:e> enhanced the APC degradation of factor Va and therefore sharpened the demarcation between the factor V Leiden-positive and -negative patients </plain></SENT>
<SENT sid="6" pm="."><plain>The sensitivity for the APCR, APCM and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FVR</z:e> was 42, 97 and 100% respectively </plain></SENT>
<SENT sid="7" pm="."><plain>The specificity for the APCR, APCM and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FVR</z:e> was 94, 96 and 100% respectively </plain></SENT>
</text></document>